Novo Nordisk shares slump after drug failure in Alzheimer’s trial
Outcome is blow to one of Europe’s largest listed companies
Related reading
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
Novo Nordisk’s ‘lottery ticket’: can obesity drugs help treat Alzheimer’s?
Results are due soon from two studies using semaglutide to treat thousands of people with the disease
New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline